<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902769</url>
  </required_header>
  <id_info>
    <org_study_id>RMB-250-18</org_study_id>
    <nct_id>NCT03902769</nct_id>
  </id_info>
  <brief_title>Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.</brief_title>
  <acronym>AML</acronym>
  <official_title>Phase II Prospective Study to Assess Rate for Prolonged Remission With Intensive Chemotherapy in Rapid Respondents AML Patients Younger Than 61 as Demonstrated by Day 5 Examination of the First Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We previously reported results of a prospective observational study demonstrating that early
      response defined as reduction in bone marrow (BM) blast counts to less than 5% of BM cells by
      the fifth day of induction therapy is a strong predictor of remission and overall survival
      (Ofran Y, et al. AJH, 2015). The long term survival benefit of early response was confirmed
      later on after a median follow-up for surviving patients of 53 months (range 17.5-84.5).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with AML, younger than 61 year of age assigned for intensive chemotherapy,
      and diagnosed with standard or intermediate risk AML, will undergo BM examination on the
      fifth day of induction. Patients in whom BM blast count at the fifth day of induction will be
      lower than 5% will proceed therapy with consolidations or autologous SCT with-holding the
      option for allo-SCT. MRD monitoring will apply to those with reliable molecular marker.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One arm open study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survivial</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>No allogeneic SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard post induction therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For slow responding AML patients, post induction therapy will be provided according to treating physician discretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prescribing conventional chemotherapy while with holding allo-SCT</intervention_name>
    <description>Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT</description>
    <arm_group_label>No allogeneic SCT</arm_group_label>
    <arm_group_label>Standard post induction therapy</arm_group_label>
    <other_name>No Allogeneic for rapid responders</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML diagnosis,

          -  treated with 3+7 Induction chemotherapy

          -  Intermediate/standard risk AML

        Exclusion Criteria:

          -  Diagnosed of APL

          -  high risk molecular/cytogenetic score
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>61 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yishai Ofran, MD</last_name>
    <phone>+972-4-7778026</phone>
    <email>y_ofran@rambam.health.gov.il</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Dr. Yishai Ofran</investigator_full_name>
    <investigator_title>Director of leukemia Service</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

